GE Medical Systems last month increased its growing investmentin the equipment maintenance sector by agreeing to acquire twocompanies that market service-related products. GE bought theU.S. healthcare insurance business of Specialty Underwriters ofOak
GE Medical Systems last month increased its growing investmentin the equipment maintenance sector by agreeing to acquire twocompanies that market service-related products. GE bought theU.S. healthcare insurance business of Specialty Underwriters ofOak Creek, WI, as well as independent service organization MaintenanceManagement, which is a subsidiary of Specialty Underwriters.
Specialty Underwriters offers healthcare maintenance insurance,in which an insurer covers a healthcare facility and pays forthe costs of equipment repair and maintenance, much as individualindemnity insurance plans do. Maintenance Management specializesin biomedical service, according to Gary Foster, GE's generalmanager of service marketing. The acquisition adds niche productsand services to GE's multivendor service business.
"It will continue our emphasis on having the broadest arrayof products for our customers," Foster said.
Both businesses were founded and owned by Michael Polaski, whowill continue to operate the non-healthcare operations of SpecialtyUnderwriters, as well as the company's healthcare maintenanceinsurance operations outside the U.S.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.